Skip to main content
Premium Trial:

Request an Annual Quote

Looking Back at Life in R&D

After 17 years at Lilly, the head of R&D at Lilly Research Laboratories Steven Paul is retiring. While speaking with R&D Directions, Paul says his accomplishments during that time include debuting three new drugs while leading the neuroscience division, redesigning the discovery aspect of the organization, and bringing in new people to keep the pipeline moving. When asked about challenges still acing the industry, Paul says is that “the industry collectively is not producing enough innovative new medicines on an annual basis to stem the loss of revenues due to patent expirations.”

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.